ENTOD Pharmaceuticals launches novel probiotic

This probiotic called Lactoshield RH is now commercially available following the advice & recommendation of an ENT specialist or rhinologist

Mumbai-based pharmaceutical company ENTOD Pharmaceuticals has launched a novel probiotic for the management of nasal allergies. Although probiotics have been traditionally used to help maintain a healthy intestinal flora that could boost immunity and overall wellness, their role in suppressing allergic reactions, particularly in the nose has been clinically studied and documented in international journals for years.

ENTOD Pharmaceuticals claims that its R&D has developed an innovative blend of specific clinically evaluated probiotic strains that together could suppress nasal allergies and be useful in managing conditions such as allergic rhinitis. This probiotic called Lactoshield RH is now commercially available following the advice & recommendation of an ENT specialist or rhinologist.

Nikkhil K Masurkar, ENTOD Pharmaceuticals CEO said, “The intestinal flora plays a vital role in modulating inflammation and immune reactions in allergic rhinitis. Studies around the world have shown that an imbalanced and unhealthy intestinal flora can trigger nasal allergic reactions. Our R&D team has isolated certain strains of lactic acid bacteria that have been shown to stabilize the intestinal microflora and improve its biodiversity, stabilising the nasal mucosa and controlling allergic reactions in the nose.

Read Previous

PFI and USAPEEC collaborate to address protein deficiency in India

Read Next

Slurrp’s Grand Biryani Celebration delights Delhi foodies and home chefs

Leave a Reply